Pharma Services

Predict immunotherapy response from live tumor biopsies

Immunotherapy has transformed cancer care — yet translating immune biology into actionable drug development insights remains one of the field’s biggest challenges. Elephas has developed elive™ to assess cytokine response in live tumor biopsies ex vivo following treatment with a therapeutic agent.

How your team can leverage elive:

  • De-risk pipeline decisions by testing assets in multiple combinations and in multiple tumor types to select the candidates with the highest potential
  • Optimize trial design by measuring tumor-immune interactions, producing biomarker candidates that reflect biologic behavior, not just expression
  • Identify likely responders by testing live tissue to assess immune response before enrollment
Contact Us

How IO development teams use elive

Translational Teams

  • Validate MOAs in human tumors 

  • Prioritize single agents and combinations across multiple tumor types

  • De-risk clinical development 

Precision Medicine Teams

  • Generate functional drug response data

  • Link functional responsiveness with molecular and immunophenotypic features

  • Identify responder and resistant phenotypes

Clinical Teams

  • Capture biology missed by PD L1, TMB, MSI, or pure genomics

  • Reduce screen failure and non responder enrollment 

  • Improve statistical power and reduce sample sizes


elive is modality-agnostic and supports functional evaluation across a diverse range of therapeutic classes, including both monotherapies and combination regimens. The platform can be applied to small molecules, antibody-based biologics, bispecific antibodies, ADCs, cell therapies, and other emerging modalities. Elephas offers pharma partners access to a range of live tumor specimens via tailored sourcing strategies within our clinical partner sites.

Real-time ICI response prediction from live tumor tissue

The ability to predict response prior to therapy initiation is transformative. Go beyond the limitations of current predictive biomarkers with elive.

The platform:

  • Uses a live core needle biopsy
  • Relies on proprietary technology to maintain TME and address tumor heterogeneity
  • Detects T-cell response to ICI treatment
  • Uses sequential treatment to replicate combination treatment

 

Explore our automated cutting tool Learn How we preserve the TME Read about our sequential treatment method

Ready to get into the details?

If you're interested in learning about how elive™ could accelerate your IO pipeline, fill out the form below and we'll be in touch.

National Advisory Group

Pooja Advani
Pooja Advani,
MBBD, MD
Medical Oncologist
Breast Cancer
Mayo Clinic
David Braun
David Braun,
MD, PhD
Medical Oncologist
Kidney Cancer
Yale School of Medicine
Christian Capitini
Christian Capitini, MD
Director
UW Health | Carbone Cancer Center
Kevin Eliceiri
Kevin Eliceiri, PhD
Professor of Microscopy, Medical Imaging & AI
The University of Wisconsin-Madison
Janis_Marie_Taube
Janis Marie Taube,
MD, MSc
Pathologist
Melanoma
Johns Hopkins Medicine